Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
02
02
2024
accepted:
18
07
2024
revised:
16
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
Research on antidepressant-related weight changes over more than 12 months is scarce and adjustment for the effects of depressive episodes has rarely been applied. Accordingly, our aim was to assess the associations of the use of any antidepressants, subclasses of antidepressant and specific compounds prior to baseline and during a 5.5-year follow-up with changes in adiposity markers, and the effect of sex on these associations, with adjustment for multiple confounders including the effects of depressive episodes and their severity. Data stemmed from a prospective cohort study including 2479 randomly selected 35-66 year-old residents of an urban area (mean age 49.9 years, 53.3% women) who underwent physical and psychiatric evaluations at baseline and follow-up. Weight, height, waist circumference, and body fat were measured by trained nurses and information on diagnosis and antidepressant use prior to baseline and during follow-up was collected through standardized interviews. In the fully adjusted models, the number of antidepressants, mainly SSRIs and TCAs, used prior to baseline, was associated with a lower increase of body-mass index (BMI, β (95%CI) = -0.12 (-0.19, -0.05)) and waist circumference (β = -0.28 (-0.56, -0.01)), whereas participants treated with antidepressants during the follow-up had a steeper increase in BMI (β = 0.32 (0.13, 0.50)) and waist circumference (β = 1.23 (0.44, 2.01)). Within the class of SSRIs, the use of fluoxetine, sertraline or escitalopram during follow-up was associated with a steeper increase in adiposity markers. The associations of SSRIs with BMI and waist circumference were only observed when the SSRIs were used during the second period of the follow-up. Sex did not moderate these associations. Our findings suggest an increase of adiposity markers during sustained treatment with TCAs and SSRIs, which however return to normal levels after cessation of treatment. Hence, the benefit of long-term administration of these antidepressants should be carefully weighed against the potential risk of weight gain.
Identifiants
pubmed: 39138155
doi: 10.1038/s41398-024-03032-5
pii: 10.1038/s41398-024-03032-5
doi:
Substances chimiques
Antidepressive Agents
0
Selective Serotonin Reuptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Informations de copyright
© 2024. The Author(s).
Références
Penninx B, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20:63–73.
pubmed: 29946213
pmcid: 6016046
doi: 10.31887/DCNS.2018.20.1/bpenninx
Mulugeta A, Zhou A, Vimaleswaran KS, Dickson C, Hypponen E. Depression increases the genetic susceptibility to high body mass index: Evidence from UK Biobank. Depress Anxiety. 2019;36:1154–62.
pubmed: 31609059
doi: 10.1002/da.22963
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, et al. Overweight, obesity, and depression a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiat. 2010;67:220–9.
pubmed: 20194822
doi: 10.1001/archgenpsychiatry.2010.2
Mannan M, Mamun A, Doi S, Clavarino A. Is there a bi-directional relationship between depression and obesity among adult men and women? Systematic review and bias-adjusted meta analysis. Asian J Psychiatry. 2016;21:51–66.
doi: 10.1016/j.ajp.2015.12.008
Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract. 2011;61:e565–72.
pubmed: 22152736
pmcid: 3162179
doi: 10.3399/bjgp11X593848
Wong J, Motulsky A, Eguale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment Indications for antidepressants prescribed in primary care in Quebec, Canada, 2006-2015. JAMA. 2016;315:2230–2.
pubmed: 27218634
doi: 10.1001/jama.2016.3445
Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong ML. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry. 2016;6:e759.
pubmed: 26978741
pmcid: 4872449
doi: 10.1038/tp.2016.25
Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res. 1988;26:265–71.
pubmed: 2975806
doi: 10.1016/0165-1781(88)90120-5
Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011;14:367–75.
pubmed: 20716398
doi: 10.1017/S1461145710000933
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71:1259–72.
pubmed: 21062615
doi: 10.4088/JCP.09r05346blu
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–70.
pubmed: 25590213
pmcid: 5393509
doi: 10.1210/jc.2014-3421
Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. Obes Rev. 2019;20:1680–90.
pubmed: 31524318
doi: 10.1111/obr.12934
Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951.
pubmed: 29793997
pmcid: 5964332
doi: 10.1136/bmj.k1951
Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression, antidepressant medication and the risk of obesity. Psychother Psychosom. 2009;78:182–6.
pubmed: 19321971
doi: 10.1159/000209349
Lamers F, Beekman AT, van Hemert AM, Schoevers RA, Penninx BW. Six-year longitudinal course and outcomes of subtypes of depression. Br J Psychiatry. 2016;208:62–68.
pubmed: 26294366
doi: 10.1192/bjp.bp.114.153098
Lasserre AM, Glaus J, Vandeleur CL, Marques-Vidal P, Vaucher J, Bastardot F, et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry. 2014;71:880–8.
pubmed: 24898270
doi: 10.1001/jamapsychiatry.2014.411
van Dijk SB, Takken T, Prinsen EC, Wittink H. Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis. Netherlands Heart J. 2012;20:208–18.
doi: 10.1007/s12471-011-0237-7
Bigaard J, Frederiksen K, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL, et al. Body fat and fat-free mass and all-cause mortality. Obes Res. 2004;12:1042–9.
pubmed: 15292467
doi: 10.1038/oby.2004.131
Haack S, Seeringer A, Thurmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10:1511–26.
pubmed: 19761372
doi: 10.2217/pgs.09.102
Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18:447–57.
pubmed: 28179816
pmcid: 5286730
doi: 10.31887/DCNS.2016.18.4/ncutler
Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23:1443–51.
pubmed: 23726508
doi: 10.1016/j.euroneuro.2013.05.001
Noordam R, Aarts N, Tiemeier H, Hofman A, Stricker BH, Visser LE. Sex-specific association between antidepressant use and body weight in a population-based study in older adults. J Clin Psychiatry. 2015;76:e745–51.
pubmed: 26132681
doi: 10.4088/JCP.13m08896
Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.
pubmed: 18366642
pmcid: 2311269
doi: 10.1186/1471-2261-8-6
Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C, et al. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry. 2009;9:9.
pubmed: 19292899
pmcid: 2667506
doi: 10.1186/1471-244X-9-9
Jebb SA, Siervo M, Murgatroyd PR, Evans S, Fruhbeck G, Prentice AM. Validity of the leg-to-leg bioimpedance to estimate changes in body fat during weight loss and regain in overweight women: a comparison with multi-compartment models. Int J Obes. 2007;31:756–62.
doi: 10.1038/sj.ijo.0803475
Hollingshead AB. Four factor index of social status. New Haven, CT: Yale University Press; 1975.
Leboyer M, Barbe B, Gorwood P, Teherani M, Allilaire JF, Preisig M, et al. Interview diagnostique pour les etudes génétiques. Paris:INSERM; 1995.
Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994;51:849–59.
pubmed: 7944874
doi: 10.1001/archpsyc.1994.03950110009002
Berney A, Preisig M, Matthey ML, Ferrero F, Fenton BT. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of alcohol and drug diagnoses. Drug Alcohol Depend. 2002;65:149–58.
pubmed: 11772476
doi: 10.1016/S0376-8716(01)00156-9
Preisig M, Fenton BT, Matthey ML, Berney A, Ferrero F. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version. Eur Arch Psychiatry Clin Neurosci. 1999;249:174–9.
pubmed: 10449592
doi: 10.1007/s004060050084
Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35:837–44.
pubmed: 678037
doi: 10.1001/archpsyc.1978.01770310043002
Leboyer M, Maier W, Teherani M, Lichtermann D, D’Amato T, Franke P, et al. The reliability of the SADS-LA in a family study setting. Eur Arch Psychiatry Clin Neurosci. 1991;241:165–9.
pubmed: 1790162
doi: 10.1007/BF02219716
American Psychiatric Association. Task Force on DSM-IV. DSM-IV-TR: diagnostic and statistical manual of mental disorders. 4th ed, text revision edn. Washington, DC: American Psychiatric Association; 2000.
Andreasen NC, Endicott J, Spitzer RL, Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry. 1977;34:1229–35.
pubmed: 911222
doi: 10.1001/archpsyc.1977.01770220111013
Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord. 1984;7:133–8.
pubmed: 6238068
doi: 10.1016/0165-0327(84)90031-4
Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry. 2001;62:256–60.
pubmed: 11379839
doi: 10.4088/JCP.v62n0407
Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170–6.
pubmed: 10450256
doi: 10.1176/ajp.156.8.1170
Kivimaki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care. 2010;33:2611–6.
pubmed: 20823343
pmcid: 2992199
doi: 10.2337/dc10-1187
Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17(Suppl 1):S37–41.
pubmed: 12404669
doi: 10.1002/hup.388
Blumenthal SR, Castro VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry. 2014;71:889–96.
pubmed: 24898363
pmcid: 9980723
doi: 10.1001/jamapsychiatry.2014.414
Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, et al. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016;5:48.
pubmed: 27089374
pmcid: 4850471
doi: 10.3390/jcm5040048
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–48.
pubmed: 17471183
pmcid: 2014120
doi: 10.1038/sj.bjp.0707253
Nihalani N, Schwartz TL, Siddiqui UA, Megna JL. Weight gain, obesity, and psychotropic prescribing. J Obes. 2011;2011:893629.
pubmed: 21318056
pmcid: 3034985
doi: 10.1155/2011/893629
Moosa MY, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol. 2003;23:549–52.
pubmed: 14624184
doi: 10.1097/01.jcp.0000095341.32154.8f
Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience. 1996;72:557–66.
pubmed: 8737424
doi: 10.1016/0306-4522(95)00566-8